{"filings":[{"id":1277636,"accession_number":"0001437749-26-021707","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-06-25T20:31:27+00:00","items":["1.02"],"status":"ready","headline":"AYTU terminates Metadate CD license agreement with Lannett","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mutual termination effective June 23, 2026; certain provisions survive per Termination Agreement.","AYTU may continue to sell existing inventory and pay royalties until sales cease.","Metadate CD net revenue for quarter ended March 31, 2026 was $49,000, de minimis.","Termination Agreement will be filed as exhibit to FY 2026 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68004,"accession_number":"0001437749-26-016717","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-05-13T20:05:56+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.","EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.","ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.","Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.","Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":41464000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92550,"accession_number":"0001437749-26-011116","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","9.01"],"status":"ready","headline":"Aytu BioPharma amends warrants to enable equity classification; expects liability reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended warrants from 2023 and 2025 offerings to clarify stockholder vote cannot change beneficial ownership blockers.","Prior classification as liabilities required recording a liability of $18.1M (Sep 2025) and $25.2M (Dec 2025).","Expects warrant liability reduction and equity increase by the same amount after amendment.","Issued unregistered in reliance on Section 3(a)(9) exchange and Section 4(a)(2) private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103465,"accession_number":"0001437749-26-002799","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.","Adjusted EBITDA -$0.8M vs +$1.3M, driven by EXXUA launch investments; cash $30.0M.","ADHD portfolio revenue $13.2M (down from $13.8M); pediatric $1.7M (down from $2.4M) due to marketing deemphasis.","EXXUA launched Dec 2025; initial stocking revenue $0.2M; 40+ person sales force deployed targeting $22B MDD market.","Cash and cash equivalents $30.0M, largely unchanged from $31.0M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":29053000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103464,"accession_number":"0001437749-26-001543","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.","Cash $32.6M as of 9/30/25; TTM adjusted EBITDA $6.7M; launch budget reduced from $10M to $6-8M.","Commercialization deal with Fabre-Kramer: $3M upfront, 28% base royalty plus 3% on COGS, milestones starting at $100M net sales.","Pivotal trials showed significant HAM-D17 improvement vs placebo (P=0.018 and P=0.032); no sexual dysfunction or weight gain warning.","Targeting 5,500 high-value psychiatry prescribers; 40+ person sales force; virtual team to deliver 20,000 contacts in launch phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119713,"accession_number":"0001437749-25-037389","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aytu BioPharma stockholders elect all director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu with majority votes.","Grant Thornton LLP ratified as independent auditor for fiscal 2026: 5,783,905 for, 257,411 against.","Non-binding advisory vote on executive compensation approved: 3,193,511 for, 311,200 against.","Approximately 60% of outstanding shares (6,083,713) present or represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119712,"accession_number":"0001437749-25-034822","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.","ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.","Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.","Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.","EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market."],"consensus_eps_estimate":-0.5202,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":13888000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136291,"accession_number":"0001437749-25-029721","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.","Q4 net revenue $15.1M (+4% YoY); net loss $19.8M vs $4.6M prior year (incl. $18.1M impairment and derivative losses).","ADHD Portfolio net revenue $57.6M (flat YoY); Pediatric Portfolio $8.8M (+20% YoY).","Cash $31.0M at June 30, 2025; 9th consecutive quarter of positive adjusted EBITDA.","EXXUA (gepirone) for MDD launch on track for Q4 2025; entering >$22B US MDD market with novel first-in-class agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136290,"accession_number":"0001437749-25-025441","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.","Termination extinguishes all obligations under the April 21, 2021 asset purchase agreement with Rumpus.","No penalties or remaining obligations for Aytu as a result of the termination.","Clinical development of AR101 had been previously suspended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153404,"accession_number":"0001437749-25-020973","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.","Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.","Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.","Follows earlier $16.6M public offering closed earlier in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153403,"accession_number":"0001437749-25-020579","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma posts updated investor presentation highlighting EXXUA opportunity","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on June 17, 2025 for use in upcoming investor meetings.","Highlights EXXUA™ (gepirone) extended-release tablets as a key pipeline asset.","No new financial guidance, operational metrics, or material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153402,"accession_number":"0001437749-25-019868","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.","Shares outstanding post-offering: 8,976,914.","EXXUA is first-in-class oral 5HT1a receptor agonist for MDD; no sexual dysfunction warning; studied in >5,000 patients.","Conference call June 11, 2025 at 4:30 p.m. ET to detail EXXUA commercialization plan.","Net proceeds for working capital and to fund EXXUA launch; expects FDA-approved product to enter $22B U.S. MDD market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153401,"accession_number":"0001437749-25-019719","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.","Granted underwriters 30-day option to purchase up to additional 1,440,000 shares of common stock.","Net proceeds of approximately $12.9M (or $14.9M if option exercised) to be used for general corporate purposes and to exclusively commercialize EXXUA (gepirone) for major depressive disorder.","Offering expected to close June 9, 2025; Lake Street Capital Markets acting as sole book runner.","Maxim Group LLC acting as lead manager and Ascendiant Capital Markets as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153400,"accession_number":"0001437749-25-019718","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.","Royalty on net sales starts at 28%, steps up to 39% when annual net sales surpass $300M; lower tier after trigger at 24.5%-35.5%.","Milestone payments range from $5M to over $100M per year based on net sales thresholds; 10% royalty on sales above $1B.","EXXUA is a first-in-class 5HT1a receptor agonist for MDD with no sexual dysfunction label warning; launch targeted for Q4 2025.","Transaction funded by cash on hand and institutional investors including Nantahala Capital, Stonepine Capital, and Aytu management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153399,"accession_number":"0001437749-25-017989","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).","All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu; each received majority vote.","Ratification of Grant Thornton LLP as auditor for fiscal 2025 approved with 4.12M for, 134k against.","Non-binding advisory vote on executive compensation passed with 2.39M for, 268k against.","Quorum of 70% (4.33M shares) present at May 21, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153398,"accession_number":"0001437749-25-016832","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.","Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.","Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.","Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.","Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":51247000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172158,"accession_number":"0001437749-25-003563","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.","Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.","Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.","Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.","Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition."],"consensus_eps_estimate":-0.0374,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":32795000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189124,"accession_number":"0001437749-24-036630","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu settles derivative shareholder suit; court hearing Jan 13, 2025","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.","Aytu to pay $250,000 in attorneys' fees and $5,000 service award to plaintiff.","Governance enhancements include new independent board member, CEO/Chair separation, enhanced insider trading oversight.","D&O defendants released; claims against Armistice defendants preserved with Aytu remaining neutral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189123,"accession_number":"0001437749-24-034898","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.","Adjusted EBITDA $1.9M, down 21% from $2.4M; cash stable at $20.1M.","ADHD Portfolio net revenue $15.3M (+1% YoY); Pediatric Portfolio up 54% sequentially.","CFO Mark Oki terminated; Ryan Selhorn appointed CFO with base salary $400K.","Board separated Chairman/CEO roles; John Donofrio appointed Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":16574000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189122,"accession_number":"0001437749-24-030297","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma signs exclusive agreement with Lupin to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.","Adzenys XR-ODT and Cotempla XR-ODT are the only extended-release orally disintegrating ADHD tablets; Health Canada approval needed.","Aytu's ADHD prescriptions grew 16.5% over two years; Canadian stimulant market was $1.1B CAD (4.5M units) in 2023.","Lupin will seek regulatory approvals over 18-24 months; financial terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205619,"accession_number":"0001437749-24-030075","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)","Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M","ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1","Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025","Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205618,"accession_number":"0001437749-24-024725","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma divests Consumer Health business to private e-commerce firm; receives royalty payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.","Aytu receives revenue-based royalty payments on future sales of former Consumer Health products.","Company now focuses solely on its prescription pharmaceutical segment to drive profitability.","Wind down eliminated materially all remaining Consumer Health expenses; near adjusted EBITDA breakeven during wind-down.","Closure of Grand Prairie, TX manufacturing site expected to further enhance operating margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222556,"accession_number":"0001437749-24-021296","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aytu BioPharma annual meeting elects all directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five incumbent directors elected with majority votes; Joshua Disbrow received 2,111,846 for, 596,291 withheld.","Ratification of Grant Thornton as auditor for FY 2024 approved: 3,290,868 for, 683,165 against.","Non-binding advisory vote on executive compensation approved: 1,978,765 for, 659,394 against.","Quorum of 73% (4,037,162 shares) represented at the June 26, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222555,"accession_number":"0001437749-24-020590","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.","Interest rate reduced ~350 bps, saving ~$1.3M over loan life; maturity extended to June 2028.","Revolving credit facility extended to June 2028 with max borrowing capacity increased to $14.5M.","Received $3.5M from exercise of 2.17M warrants at $1.59; $2M used to pay down term loan.","Shares outstanding 5,972,327 as of June 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222554,"accession_number":"0001437749-24-017058","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.","ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.","Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.","TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.","Cash $19.8M; manufacturing transition expected to improve margins."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":63026000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242075,"accession_number":"0001437749-24-004155","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.","ADHD Portfolio revenue jumped 49% to $16.6M; Rx Segment gross margin improved to 78% from 72%.","Operating income $2.4M vs. operating loss of $6.9M a year ago; net loss narrowed to $0.2M from $6.7M.","Adjusted EBITDA $5.1M (up 599% YoY); cash $19.5M at Dec 31, 2023.","Company winding down Consumer Health Segment to focus on Rx Segment; expects neutral segment EBITDA for FY2024."],"consensus_eps_estimate":-0.0374,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":45033000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259473,"accession_number":"0001558370-23-019194","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.","Initial term from Nov 13, 2023 to Nov 13, 2028; auto-renews for successive 3-year terms.","Company must purchase 100% of its requirements for covered products from Halo, except for own manufacturing.","Company supplies active ingredients; Halo handles manufacturing, QC, packaging, and validation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259472,"accession_number":"0001558370-23-019023","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.","ADHD net revenue $15.1M, up 31% YoY; pediatric revenue $2.6M impacted by payor changes.","Net loss $8.1M ($1.48/sh) vs $0.7M loss last year; includes $5.9M loss on derivative warrant liabilities.","Adjusted EBITDA $2.2M vs $1.7M YoY; Rx segment Adjusted EBITDA $2.4M.","Cash $20.0M at Sept 30, 2023; FDA approvals for manufacturing site transfers for Adzenys and Cotempla."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":22099000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259471,"accession_number":"0001558370-23-016776","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma receives FDA approval for Cotempla XR-ODT site transfer, expects margin boost in 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Cotempla XR-ODT Prior Approval Supplement (PAS) for manufacturing transfer to contract manufacturer.","Adzenys XR-ODT received similar PAS approval in April 2023; both ADHD brands moving to contract production.","Company expects enhanced ADHD product margins starting calendar 2024 after exiting Grand Prairie facility.","Production ramp-up expected late 2023; Adzenys production already underway at contract manufacturer.","CEO cites multi-year effort: bioequivalence studies, strong contract partners, and regulatory navigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259470,"accession_number":"0001558370-23-016284","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aytu BioPharma COO resigns; company winding down manufacturing, suspending R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Christopher Brooke resigned effective Oct 13, 2023, to join a development-stage biotech.","Company will not replace COO due to wind down of manufacturing at Grand Prairie, TX facility.","All pipeline research and development programs are indefinitely suspended.","Resignation not due to any disagreement with company or auditors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276745,"accession_number":"0001558370-23-016076","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).","Net loss improved to $2.5M ($0.59/share) from $16.1M ($8.95/share) a year ago; $0.6M net income excluding impairment.","Adjusted EBITDA positive $7.7M in Q4 vs negative $3.9M; FY23 Adj. EBITDA positive $3.2M vs negative $21.5M.","Cash ended at $23.0M, up from $19.2M in March; company plans to monetize or discontinue Consumer Health segment.","Gross margin improved to 60% (Q4) and 62% (FY) from 54% in both prior-year periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276744,"accession_number":"0001558370-23-014996","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aytu BioPharma approves $118K CEO bonus and $83K CFO bonus for 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Joshua R. Disbrow awarded $118,000 bonus (33% of target).","CFO Mark K. Oki awarded $83,000 bonus (50% of target).","Bonuses to be paid in January 2024; full payment if employment terminates early.","Approved by Compensation Committee on August 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276743,"accession_number":"0001558370-23-012506","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu BioPharma signs exclusive deal with Medomie Pharma for ADHD drugs in Israel, Palestinian Authority","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive collaboration, distribution and supply agreement for Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority.","Medomie will seek local regulatory approvals and marketing authorizations; first international commercial agreement for these ADHD products.","Aytu CEO Josh Disbrow cites potential to improve patient compliance and reduce therapy misuse in underserved markets.","No financial terms disclosed; export to Medomie after regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276742,"accession_number":"0001558370-23-011769","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aytu submits Cotempla XR-ODT site transfer PAS to FDA; expects 15% margin improvement on ADHD brands","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted Cotempla XR-ODT Prior Approval Supplement to FDA; expects six-month review with approval by late 2023/early 2024.","Adzenys XR-ODT site transfer PAS already approved; production shifting to contract manufacturer.","Upon completion of both site transfers, expects ~15% margin improvement for ADHD product line.","CEO states outsourced manufacturing of Adzenys and Cotempla expected to begin by late 2023/early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294549,"accession_number":"0001104659-23-070444","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma prices $4M at-the-market offering, appoints new director, extends loan interest-only period","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.","Abhinav Jain of Nantahala Capital appointed to Board; Board increases from 4 to 5 members.","Company to focus on Rx segment, de-emphasize or monetize Consumer Health segment, suspend pipeline programs.","Closing of offering extends interest-only period on $15M Avenue Capital term loan through maturity in January 2025.","Common warrants (Tranche A & B) exercisable at $1.59/share for up to 4.35M shares; potential additional $7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294548,"accession_number":"0001558370-23-010277","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"AYTU Biopharma stockholders approve 2023 equity incentive plan and elect all director nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; For votes ranged 673,707–685,411, Withheld 304,133–315,837.","2023 Equity Incentive Plan approved: 632,357 For, 352,359 Against, 4,828 Abstain; 952,620 broker non-votes.","Ratification of Grant Thornton as independent auditor approved: 1,754,922 For, 132,135 Against, 55,107 Abstain.","Advisory vote on executive compensation approved (non-binding): 587,253 For, 383,698 Against, 18,593 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294547,"accession_number":"0001558370-23-009383","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.","Record total prescriptions 153,452 (+32% YoY); ADHD prescriptions up 27%.","Rx segment revenue $13.8M; ADHD revenue down 21% to $8.3M due to $1.2M channel inventory adjustment.","Pediatric products revenue up 81% to $5.3M; Consumer Health down 14% to $8.9M.","Gross margin improved to 56% from 52%; cash $19.2M; FDA approval for Adzenys manufacturing transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":76667000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294546,"accession_number":"0001558370-23-007404","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aytu BioPharma subleases 22,909 sq ft of manufacturing facility to AMTMS; to expand to entire facility by Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subleases 22,909 sq ft (~30%) of Grand Prairie, TX facility to AMTMS; base rent $20,045/mo through Dec 2023, then $21,000/mo until expansion.","Expansion to entire 77,112 sq ft facility by Dec 31, 2024; rent rises to $70,686/mo. Security deposit of $90,731.","CEO says sublease reduces monthly operating expenses, supports margin improvement for ADHD products; longer-term plan to transfer manufacturing to contract manufacturer.","AMTMS is a new CMO; will use facility for nutraceutical and pharmaceutical manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294545,"accession_number":"0001558370-23-006964","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma gets FDA approval for Adzenys site transfer; 15% margin improvement expected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Prior Approval Supplement to transfer Adzenys XR-ODT manufacturing to contract manufacturer in 2023.","Cotempla XR-ODT bioequivalence study completed; site transfer PAS submission expected mid-2023 with approval by late 2023 or early 2024.","Upon completion of both site transfers, Aytu expects 15% margin improvement for ADHD product line.","Manufacturing of Adzenys and Cotempla at contract facility expected to begin late 2023 and early 2024 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294544,"accession_number":"0001558370-23-006188","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aytu BioPharma explores strategic alternatives and financing to address liquidity; SEC inquiry ongoing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary discussions underway for potential strategic transactions and financing options.","Company cites ongoing liquidity needs; no assurance that any deal will materialize.","Equity financings would provide liquidity but could be dilutive to existing stockholders.","SEC inquiry active regarding proposed restatements; timing of restatement and Q2 10-Q filing uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315151,"accession_number":"0001104659-23-037122","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Aytu BioPharma increases Eclipse revolving credit facility by $2M to $14.5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Eclipse Amendment No. 4 increased revolving loan commitment by $2M, total facility now $14.5M.","Borrowing remains subject to borrowing base and reserve requirements.","Avenue Amendment permits the Eclipse facility increase; no other terms changed.","Loan agreements dated back to 2019; amendments align with existing debt structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315150,"accession_number":"0001558370-23-001642","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aytu BioPharma Q2 FY2023 revenue $26.3M (+14% YoY); second consecutive positive adjusted EBITDA $0.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.","Adjusted EBITDA positive $0.7M vs $(7.6)M loss in year-ago quarter; second consecutive positive quarter.","Net loss $(6.7)M ($2.15 per share) improved from $(11.5)M ($8.74 per share) in Q2 FY2022.","Gross margin expanded to 66% from 53% YoY; suspension of clinical programs expected to save over $20M.","Extended interest-only period on Avenue loan to Jan 2024; 1-for-20 reverse stock split regained Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":53934000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315149,"accession_number":"0001104659-23-023779","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Aytu BioPharma restates Q1 FY2023 financials; warrant misclassification adds $5.6M liabilities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concludes Sep 30, 2022 financials should be restated due to warrant misclassification as equity instead of liabilities.","Restatement increases total liabilities by $5.6M, decreases equity by $3.4M, and reduces net loss by $2.2M.","Material weakness in internal control over financial reporting identified; company working to remediate.","Company expects to file 10-Q/A for Sep quarter and then 10-Q for Dec quarter as soon as practicable.","Going forward, warrants will be classified as liabilities, which may adversely affect results of operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315148,"accession_number":"0001558370-23-001236","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["7.01","9.01","99.1"],"status":"ready","headline":"Aytu BioPharma delays Q2 FY2023 filing due to warrant accounting matter; believes no impact on revenue, cash, or EBITDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delayed filing of Form 10-Q for quarter ended Dec 31, 2022 pending management review of warrant accounting from prior financings.","Company states the matter will not affect assets, cash, revenue, cost of goods sold, operating expenses, loss from operations, or adjusted EBITDA.","Quarterly conference call rescheduled; company intends to file the quarterly report as soon as practicable.","No restatement or adjustment to previously reported financial metrics expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315147,"accession_number":"0001104659-23-020220","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.","CFO Oki’s agreement modified to conform equity acceleration and Cause definition changes including willful malfeasance standard.","Cause definitions revised across both agreements: willful malfeasance/willful misconduct replaces material misconduct and gross negligence.","Both amendments supersede prior employment agreements; terms approved by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315146,"accession_number":"0001558370-23-000493","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on Jan 23, 2023 confirming bid price compliance.","Closing bid price exceeded $1.00 for 10 consecutive business days (Jan 6-20, 2023).","Company is now fully compliant with all Nasdaq listing rules; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315145,"accession_number":"0001104659-23-001400","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Aytu BioPharma enacts 1-for-20 reverse stock split to regain Nasdaq $1.00 bid compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-20 reverse split reduces outstanding shares from ~68.8M to ~3.4M.","Company must maintain closing bid ≥$1.00 for 10 consecutive days by May 22, 2023 to comply with Nasdaq.","Proportional adjustments to warrants, options, and equity plan pool; no fractional shares—cash in lieu.","New CUSIP 054754858; shares continue trading under ticker AYTU on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333487,"accession_number":"0001558370-22-019046","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["8.01","9.01","99.1"],"status":"ready","headline":"Aytu settles derivative lawsuits over 2021 option grants; cancels 25% of awards, adds independent directors","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement cancels 387,804 of 1,551,216 shares (25%) from 2021 option grants to directors and officers.","Company to add two independent directors within six months; one appointed as Compensation Committee chair.","Non-employee director compensation capped at $175,000 annually through 2024; new equity plan with reserve ≤15% of outstanding.","No further equity awards to defendants under 2015 plan; lead independent director to be designated.","Aytu to pay up to $425,000 in attorneys' fees; no admission of wrongdoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333486,"accession_number":"0001558370-22-018991","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Gary Cantrell to retire from Aytu BioPharma board effective Dec. 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Cantrell notified Aytu BioPharma of his intention to retire from the Board, effective December 31, 2022.","Mr. Cantrell did not advise the Company of any disagreement with its operations, policies, or practices.","Aytu is initiating a search for an additional member of the Board of Directors.","The retirement is a planned departure, not due to any dispute or controversy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333485,"accession_number":"0001558370-22-018607","cik":1385818,"company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Aytu BioPharma dismisses Plante & Moran, appoints Grant Thornton as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Plante & Moran on Dec 12, 2022; reports had no adverse opinions but FY2022 included going concern explanatory paragraph.","Appointed Grant Thornton LLP as independent auditor for fiscal year 2023.","No disagreements on accounting principles; material weakness in impairment analysis previously reported and remediated.","Grant Thornton had not been consulted on any accounting matters prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23613056.923076924,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-13T23:59:59+00:00|333485"}